Format

Send to

Choose Destination
CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10.

Current recommendations and recent progress in endometrial cancer.

Author information

1
Associate Professor, Department of Gynecologic Oncology, The University of Chicago, Chicago, IL.
2
Dr. Brooks is now the Associate Professor and Chief of the Division of Gynecologic Oncology, University of California Davis School of Medicine, Davis, CA.
3
Professor of Medicine and Director, Medical Oncology Breast Program, Department of Medical Oncology, The University of Chicago, Chicago, IL.
4
Assistant Professor, Department of Pathology, The University of Chicago, Chicago, IL.
5
Assistant Professor of Obstetrics and Gynecology, Department of Gynecologic Oncology, The University of Chicago, Chicago, IL.
6
Associate Professor of Obstetrics and Gynecology, Department of Gynecologic Oncology, The University of Chicago, Chicago, IL.
7
Assistant Professor, Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL.
8
Resident, Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL.
9
Instructor of Medicine, Division of Gynecologic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Abstract

Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite-instable, metastatic disease, anti- programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.

KEYWORDS:

endometrial cancer; health disparities; microsatellite instability; uterine cancer

PMID:
31074865
DOI:
10.3322/caac.21561
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center